Latest Breaking News On - Danielc cattran - Page 1 : vimarsana.com

ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results

Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with. | May 12, 2023

Fernandoc fervenzaDouglas golenbockMargery blacklowDanielc cattranStephenc gloverCasey mcdonaldRichardj glassockDave schemeliaUmass chan medical schoolDivision of infectious diseasesZyversa therapeutics incSecurities exchangeNephrology collaborative groupMayo graduate school of medicineDavid geffen school of medicineUniversity of toronto

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

/PRNewswire/ ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for.

United statesAlessia fornoniDanielc cattranSharong adlerFernandoc fervenzaDebbies gipsonStephenc gloverPabloa guzmanPablo guzmanMarlene haffnerDivision of nephrologyUniversity of torontoFounder of orphan solutionsProducts developmentDepartment of pediatrics at university michiganKatz family division of nephrology

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

/PRNewswire/ ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for.

United statesAlessia fornoniDanielc cattranSharong adlerFernandoc fervenzaDebbies gipsonStephenc gloverPabloa guzmanPablo guzmanMarlene haffnerDivision of nephrologyUniversity of torontoFounder of orphan solutionsProducts developmentDepartment of pediatrics at university michiganKatz family division of nephrology

ZyVersa (ZVSA) Appoints Daniel C Cattran and Fernando C Fervenza to its Advisory Board

ZyVersa (ZVSA) Appoints Daniel C Cattran and Fernando C Fervenza to its Advisory Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlessia fornoniDanielc cattranSharong adlerFernandoc fervenzaDebbies gipsonStephenc gloverPabloa guzmanPablo guzmanMarlene haffnerNephrology fellowship training program atKidney research network coordinating centerUniversity of torontosenior scientistZyversa therapeutics incDivision of nephrologyUniversity of miami miller school medicine

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

Drs. Daniel C. Cattran and Fernando C. Fervenza join ZyVersa s distinguished group of Scientific AdvisorsVAR 200 is a phase 2a-ready cholesterol e.

United statesAlessia fornoniDanielc cattranSharong adlerFernandoc fervenzaDebbies gipsonStephenc gloverPabloa guzmanPablo guzmanMarlene haffnerDivision of nephrologyUniversity of torontoFounder of orphan solutionsProducts developmentDepartment of pediatrics at university michiganKatz family division of nephrology